Alla studier
RekryteringFAS3INTERVENTIONELL

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

High cholesterol, particularly 'bad' LDL cholesterol, can build up in blood vessels and raise the risk of heart attacks and strokes. While many people manage their cholesterol with standard medications like statins, some still have high levels even on the highest dose they can comfortably take. This Phase 3 clinical trial compares an experimental medicine called obicetrapib against an approved treatment called bempedoic acid. Researchers want to see which tablet lowers LDL cholesterol more effectively and safely over approximately 12 weeks (84 days). The trial is open to adults aged 18 and older who are at high risk of heart problems. To ensure a fair comparison, every participant will receive one active medicine alongside a matching dummy pill. You will receive regular check-ups and blood tests throughout the trial to monitor your health and cholesterol levels closely.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
A. Menarini International Licensing S.A.
Inskrivningsmål
426
Starta
06 May 2026
Beräknad slutförande
01 Jan 2027

Vad handlar denna studie om?

Cholesterol is a fatty substance found in your blood. While your body needs some cholesterol to work properly, having too much low-density lipoprotein (often called 'bad' LDL cholesterol) can cause fatty deposits to build up in your arteries. Over time, this narrowing increases the likelihood of serious cardiovascular events, such as heart attacks and strokes. Many patients take cholesterol-lowering tablets, such as statins, to protect their heart health. However, some people cannot reach a safe cholesterol level with standard treatments alone.

This study evaluates a new investigational tablet called obicetrapib. Obicetrapib works by blocking a specific protein (called CETP) that is involved in processing fats in the blood, helping the body clear more bad cholesterol. To measure how well it works, researchers are testing it directly against bempedoic acid, another medication already used to lower cholesterol. The main goal is to compare how effectively these two medicines reduce LDL cholesterol after 12 weeks of daily treatment.

Finding new ways to manage cholesterol is vital for individuals at high risk of heart complications who need additional support. If obicetrapib proves to be safe and effective, it could provide doctors with an important new treatment option to help protect people from cardiovascular disease in the future.

Viktiga punkter

  • A Phase 3 study comparing two cholesterol-lowering tablets: obicetrapib and bempedoic acid.
  • Aimed at adults at high risk of heart problems whose cholesterol remains high despite current treatment.
  • Every participant receives an active treatment taken once daily for about 12 weeks.
  • Involves regular clinic visits and blood tests to monitor your health and safety.
  • Taking part is voluntary and does not replace your standard NHS medical care.

Vem kan vara berättigad?

This study is designed for adults aged 18 and over who have high cholesterol and are considered at high or very high risk of heart disease. To be eligible, you must have been taking your current cholesterol-lowering medicines (such as statins, ezetimibe, or injectable treatments) at a stable, maximum tolerated dose for at least eight weeks, yet still have cholesterol levels that remain above the target range. Women taking part must not be pregnant, breastfeeding, or planning a pregnancy during the trial.

You will not be able to take part if you have a known inherited genetic condition that causes very high cholesterol, known as familial hypercholesterolaemia. The trial also excludes individuals with severe heart failure, those who have suffered a heart attack or stroke within the past three months, or anyone with poorly controlled high blood pressure, severe diabetes, or active liver conditions.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I am aged 18 or older.
  2. I have high cholesterol and have been told I am at high risk of heart problems.
  3. I have been taking my highest tolerated dose of cholesterol medicine for at least 8 weeks.
  4. I have not had a heart attack, stroke, or heart surgery in the last 3 months.
  5. I do not have severe heart failure, active liver disease, or an inherited cholesterol disorder.
  6. I am not pregnant, breastfeeding, or planning to become pregnant.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

Taking part in this study lasts for approximately 12 weeks (84 days). Participants are randomly assigned to take either obicetrapib or bempedoic acid once a day by mouth. To make sure results are unbiased, the study uses a 'double-dummy' design: you will take two sets of pills daily (one active medication and one identical dummy pill), meaning every person receives an active medicine. During the study, you will continue your usual cholesterol treatment and attend scheduled clinic appointments. At these visits, doctors will monitor your health through blood tests, blood pressure checks, and physical examinations.

Potentiella risker och fördelar

Taking part offers the possibility of lowering your bad cholesterol and provides close, specialised monitoring of your heart health throughout the study period. However, as with any medicine, there may be side effects, which the medical team will explain in full detail before you join. There is also no guarantee that the treatment will improve your condition. Joining the study is entirely your choice, and you are free to leave at any time without giving a reason and without affecting your normal NHS care.

Platser (1)

  • FutureMeds North Tees
    Verifierat postnummer
    Stockton-on-Tees, United Kingdom· Rekrytering

Vanliga frågor

Will I definitely receive an active medicine?

Yes. This study does not use a placebo-only group. Everyone receives an active cholesterol-lowering treatment (either obicetrapib or bempedoic acid) along with a matching dummy tablet.

Do I have to stop taking my current statin?

No. You will continue to take your regular cholesterol-lowering medicines at your usual stable dose throughout the trial.

Does taking part cost anything?

No. The trial medication, clinic visits, and all required tests are provided free of charge, and travel expenses are usually reimbursed.

Vad händer om jag upplever biverkningar?

The trial doctors will monitor you closely at every visit. You will also be given contact details for the study team so you can reach them at any time if you feel unwell.

Can I leave the study early if I change my mind?

Yes. Participation is entirely voluntary, and you can withdraw at any point without your standard healthcare or relationship with your doctor being affected.

Hur du får reda på mer

Andrea Conte, Medical Doctor

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tole…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.